I think that almost everyone would agree that making good choices requires access to good information. That may be especially true with regard to choices about one’s health, where the stakes are high, the issues are often complicated, and there is a lot of uncertainty. That is why I feel so strongly that promoting patient access to clinical data is the right thing to do, that it drives better care, and that patients will increasingly demand it.
Here is another, more personal, reason why I feel strongly about it.
Best wishes for a happy and healthy New Year.
Perhaps you have heard the rather grim joke about how doctors don’t know when to stop treating patients who no longer benefit. It goes something like this: The oncologist goes to the cemetery to find (and treat) Mrs. Jones, since she hasn’t “seen” the latest chemo-cocktail for her recently fatal malignancy. When he asks the grave-digger why she isn’t in her assigned plot, he is told that she is off getting dialysis. Bah dum bump. OK, so it is crude, but everybody “gets” it, because it is just an exaggeration of the kind of aggressive, low-utility care that we often see (or “provide”) at the end of life.
Readers of this blog know that I believe that we, as physicians, often fail our patients by doing more than we would want done for ourselves. I have generally considered this a distinctly “American” issue, fueled in part by unreasonable expectations of the utility of medical interventions, the entrepreneurial nature of a lot of US health care, and the prevalent American sentiment that death is somehow “optional,” or at least to be opposed vigorously at all times regardless of the circumstances.
A recent paper in Heart provided a little international – and, alas, cardiology — flavor.
In it, researchers from the UK, Israel, and France reported on their experience performing primary percutaneous coronary interventions (PCI) for acute ST-segment elevation myocardial infarctions (STEMI) in nonagenarians. It was a retrospective analysis of a series of 145 patients with no control group, which almost certainly means that there was a strong selection bias toward treating only “the best” nonagenarians. The principal finding was a 24% in-hospital mortality, with a 6 month mortality of 39% and 1 year mortality of 47%. Here is what the survival curve looked like:
Continue reading No Way Out
My first posting on this blog explained why I chose to name it “Auscultation.” I wrote that I wanted to promote a conversation, and that listening was essential to doing so. I went on to write: “With an obvious nod to my being a cardiologist, I believe auscultation has long been an act that defines us as physicians and connects us in a profound way with our patients. The act of leaning in, touching the patient, listening, concentrating, and interpreting is a powerful metaphor for the entire clinical encounter: getting close to the patient and listening.”
It is therefore no wonder that I was really pleased to read “The Physical Examination and the Fifth Maneuver” by Thomas Metkus in a recent issue of the Journal of the American College of Cardiology. The piece appeared in the “fellows in training and early career page” in the Journal, which regularly features articles by trainees about their experiences, and was a mature and robust defense of the importance of developing auscultatory skills. Metkus alludes to Osler’s model of physical diagnosis, the first four maneuvers of which are inspection, percussion, palpation and auscultation. The fifth – and arguably most important – is cognition, the intellectual exercise of putting it all together.
Continue reading Listen More
There were several news stories last week that reported that Pfizer had abandoned its efforts to have its Lipitor brand of atorvastatin made available over the counter, without a prescription. I was never a big fan of OTC statins (more on that later) but I was struck by the reason that Pfizer put out:
The study did not meet its primary objectives of demonstrating patient compliance with the direction to check their low-density lipoprotein cholesterol (LDL-C) level and, after checking their LDL-C level, take appropriate action based on their test results.
Left unstated (and unclear) in this is exactly what the appropriate action was supposed to be. I guess they were implying that patients were supposed to check how they responded to the drug and then figure out if they should keep taking it, change the dose or seek professional advice about next steps.
Continue reading Right Call; Wrong Reason
Every so often I come across a research paper that leaves me feeling as if I am glimpsing the future. I had that experience when I came across the work of Cingolani and colleagues in the December 23 issue of the Journal of the American College of Cardiology (volume 64, no. 24). The paper, entitled “Engineered electrical conduction tract restores conduction in complete heart block: from in vitro to in vivo proof of concept” details a new approach to an old problem.
Here’s the problem. Many people develop serious disturbances of the heart rhythm based on deterioration or destruction of specialized “conduction tissue” within the heart. This tissue is responsible for transmitting the electrical impulses that govern the beating of the heart. In the case of the dysfunction of conduction tissue between the atria and ventricles, the chambers become electrically and mechanically dissociated – a condition termed complete heart block, and generally treated with an implanted pacemaker.
Continue reading Department of Really Cool Ideas